NeuBase Capital Stock vs Net Debt Analysis
| NBSE Stock | USD 0.44 0.02 4.76% |
NeuBase Therapeutics financial indicator trend analysis is infinitely more than just investigating NeuBase Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NeuBase Therapeutics is a good investment. Please check the relationship between NeuBase Therapeutics Capital Stock and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.
Capital Stock vs Net Debt
Capital Stock vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NeuBase Therapeutics Capital Stock account and Net Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between NeuBase Therapeutics' Capital Stock and Net Debt is 0.49. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Net Debt in the same time period over historical financial statements of NeuBase Therapeutics, assuming nothing else is changed. The correlation between historical values of NeuBase Therapeutics' Capital Stock and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of NeuBase Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Capital Stock i.e., NeuBase Therapeutics' Capital Stock and Net Debt go up and down completely randomly.
Correlation Coefficient | 0.49 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from NeuBase Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NeuBase Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.At present, NeuBase Therapeutics' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.22, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.17.
| 2020 | 2021 | 2023 | 2024 (projected) | Cost Of Revenue | 575.5K | 1.3M | 1.1M | 1.1M | Research Development | 14.4M | 21.4M | 19.3M | 18.3M |
NeuBase Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
NeuBase Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NeuBase Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 12.5M | 34.4M | 64.2M | 32.7M | 37.6M | 39.5M | |
| Short Long Term Debt Total | 122.9K | 138.6K | 6.5M | 6.0M | 6.9M | 7.2M | |
| Other Current Liab | 496.3K | 950.2K | 1.7M | 1.7M | 1.9M | 2.0M | |
| Total Current Liabilities | 2.5M | 3.1M | 4.2M | 4.2M | 4.8M | 5.0M | |
| Total Stockholder Equity | 10.0M | 31.3M | 54.1M | 23.2M | 26.7M | 14.0M | |
| Property Plant And Equipment Net | 431.0K | 1.2M | 8.4M | 7.8M | 8.9M | 9.4M | |
| Net Debt | (10.2M) | (31.9M) | (46.4M) | (17.2M) | (19.7M) | (20.7M) | |
| Retained Earnings | (27.0M) | (43.6M) | (69.0M) | (102.7M) | (92.5M) | (87.8M) | |
| Non Current Assets Total | 1.5M | 1.6M | 9.2M | 8.0M | 9.3M | 5.5M | |
| Non Currrent Assets Other | 338.9K | 145.3K | 414.0K | 273.2K | 314.2K | 298.5K | |
| Cash And Short Term Investments | 10.3M | 32.0M | 52.9M | 23.2M | 26.6M | 28.0M | |
| Common Stock Shares Outstanding | 413.6K | 981.0K | 1.4M | 1.6M | 1.9M | 2.0M | |
| Liabilities And Stockholders Equity | 12.5M | 34.4M | 64.2M | 32.7M | 37.6M | 39.5M | |
| Non Current Liabilities Total | 1.6M | 1.6M | 5.9M | 5.3M | 6.1M | 6.4M | |
| Other Stockholder Equity | 37.0M | 74.9M | 123.0M | 125.9M | 144.8M | 152.1M | |
| Total Liab | 2.5M | 3.1M | 10.1M | 9.5M | 10.9M | 11.5M | |
| Property Plant And Equipment Gross | 431.0K | 1.2M | 8.9M | 9.1M | 10.4M | 10.9M | |
| Total Current Assets | 11.0M | 32.8M | 54.9M | 24.6M | 28.3M | 29.8M | |
| Short Term Debt | 122.9K | 138.6K | 638.6K | 660.7K | 759.8K | 797.8K | |
| Common Stock | 1.7K | 2.3K | 3.3K | 3.3K | 3.0K | 2.8K | |
| Accounts Payable | 1.5M | 1.5M | 1.8M | 1.8M | 1.7M | 1.6M | |
| Cash | 10.3M | 32.0M | 52.9M | 23.2M | 20.8M | 19.8M | |
| Other Current Assets | 265.7K | 294.6K | 2.0B | 1.5M | 1.7M | 1.6M | |
| Net Tangible Assets | 9.9M | 31.3M | 54.1M | 23.2M | 26.7M | 22.1M | |
| Property Plant Equipment | 431.0K | 1.2M | 8.4M | 7.8M | 8.9M | 9.4M | |
| Short Long Term Debt | 73.2K | 122.9K | 138.6K | 148.4K | 170.6K | 124.2K | |
| Net Invested Capital | 10.2M | 31.4M | 54.2M | 23.2M | 26.7M | 28.0M | |
| Net Working Capital | 8.5M | 29.7M | 50.7M | 20.5M | 23.6M | 22.1M | |
| Capital Stock | 1.7K | 2.3K | 3.3K | 3.3K | 3.0K | 2.6K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuBase Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.